WO2019241641A3 - Méthodes de traitement du cancer - Google Patents

Méthodes de traitement du cancer Download PDF

Info

Publication number
WO2019241641A3
WO2019241641A3 PCT/US2019/037204 US2019037204W WO2019241641A3 WO 2019241641 A3 WO2019241641 A3 WO 2019241641A3 US 2019037204 W US2019037204 W US 2019037204W WO 2019241641 A3 WO2019241641 A3 WO 2019241641A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer treatment
treatment methods
methods
tautomer
stereoisomer
Prior art date
Application number
PCT/US2019/037204
Other languages
English (en)
Other versions
WO2019241641A2 (fr
Inventor
Stuart F. J. LE GRICE
David L. Spector
Wenbo XU
Fardokht A. ABULWERDI
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Cold Spring Harbor Laboratory filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2019241641A2 publication Critical patent/WO2019241641A2/fr
Publication of WO2019241641A3 publication Critical patent/WO2019241641A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement du cancer chez un patient en ayant besoin, le cancer présentant une régulation à la hausse de MALAT1, comprenant l'administration au patient d'une quantité efficace d'un composé de formule (I) ou (II), son tautomère, son stéréoisomère, son sel pharmaceutiquement acceptable, ou toute combinaison de ceux-ci : où R1, R2, R3, R4, R5, X et m sont tels que décrits dans la description. L'invention concerne également des procédés d'inhibition de la morphogenèse de ramification dans une culture de cellules organoïdes tumorales comprenant la mise en contact de la culture cellulaire avec un composé de formule (I) ou (II), son tautomère, son stéréoisomère, son sel pharmaceutiquement acceptable, ou toute combinaison de ceux-ci. Dans les formules (I) et (II), R1, R2, R3, R4, R5, X et m sont tels que décrits dans la description.
PCT/US2019/037204 2018-06-14 2019-06-14 Méthodes de traitement du cancer WO2019241641A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685026P 2018-06-14 2018-06-14
US62/685,026 2018-06-14

Publications (2)

Publication Number Publication Date
WO2019241641A2 WO2019241641A2 (fr) 2019-12-19
WO2019241641A3 true WO2019241641A3 (fr) 2020-02-20

Family

ID=67263054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/037204 WO2019241641A2 (fr) 2018-06-14 2019-06-14 Méthodes de traitement du cancer

Country Status (1)

Country Link
WO (1) WO2019241641A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210012588A (ko) * 2019-07-26 2021-02-03 아주대학교산학협력단 Tlr7 및 tlr9의 신호전달 경로를 억제하는 신규한 소분자 화합물 및 그 용도
CN114504649A (zh) * 2022-02-22 2022-05-17 山东大学齐鲁医院 Malat1抑制剂在腹主动脉瘤防治中的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FARDOKHT A. ABULWERDI ET AL: "Selective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1", ACS CHEMICAL BIOLOGY, vol. 14, no. 2, 8 January 2019 (2019-01-08), pages 223 - 235, XP055622444, ISSN: 1554-8929, DOI: 10.1021/acschembio.8b00807 *
GAYATRI ARUN ET AL: "Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss", GENES AND DEVELOPMENT., vol. 30, no. 1, 23 December 2015 (2015-12-23), US, pages 34 - 51, XP055622098, ISSN: 0890-9369, DOI: 10.1101/gad.270959.115 *
GRYSHCHENKO A A ET AL: "Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1,2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, ELSEVIER, NL, vol. 24, no. 9, 21 March 2016 (2016-03-21), pages 2053 - 2059, XP029500711, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2016.03.036 *
KAITLIN J. BASHAM ET AL: "Chemical Genetic Screen Reveals a Role for Desmosomal Adhesion in Mammary Branching Morphogenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 4, 25 January 2013 (2013-01-25), US, pages 2261 - 2270, XP055661726, ISSN: 0021-9258, DOI: 10.1074/jbc.M112.411033 *
MASASHI TANIGUCHI ET AL: "Inhibition of malignant phenotypes of human osteosarcoma cells by a gene silencer, a pyrrole-imidazole polyamide, which targets an E-box motif", FEBS OPEN BIO, vol. 4, no. 1, 1 January 2014 (2014-01-01), US, pages 328 - 334, XP055622102, ISSN: 2211-5463, DOI: 10.1016/j.fob.2014.03.004 *
SMIRNOVA, T. A. ET AL: "Method for preparation of 1-methyl-5-aryl-2-aminoimidazoles and their reactivity", IZVESTIYA TIMIRYAZEVSKOI SEL'SKOKHOZYAISTVENNOI AKADEMII, no. 4, 2003, pages 132 - 141, XP009516129 *
SUNING CHEN ET AL: "A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report", CELLULAR ONCOLOGY, vol. 41, no. 1, 8 November 2017 (2017-11-08), Dordrecht, pages 93 - 101, XP055622086, ISSN: 2211-3428, DOI: 10.1007/s13402-017-0356-2 *

Also Published As

Publication number Publication date
WO2019241641A2 (fr) 2019-12-19

Similar Documents

Publication Publication Date Title
WO2016118951A3 (fr) Inhibiteurs d'itk hétérocycliques pour traiter l'inflammation et le cancer
MX2020013373A (es) Compuestos de naftiridinona utiles como activadores de celulas t.
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
WO2017087808A8 (fr) Composés hétérocycliques inhibant l'activité kinase de mnk utiles pour le traitement de divers cancers
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
WO2015095834A3 (fr) Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
CA2902116C (fr) Derives de pyrrolopyridine et leur utilisation en tant qu'inhibiteurs del'activite amine oxydase sensible au semicarbazide (ssao)
MX2022000310A (es) Inhibidores de proteina bcl-2.
WO2020033838A3 (fr) Traitement du cancer à egfr mutant
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP4342473A3 (fr) Composés utiles dans la thérapie du vih
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
MX2022000143A (es) Metodos novedosos.
WO2019241641A3 (fr) Méthodes de traitement du cancer
WO2019199667A3 (fr) Certains composés de pladiénolide et procédés d'utilisation
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2019191279A3 (fr) Composés ayant une activité antitumorale contre des cellules cancéreuses portant des mutations her2 exon 19
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19739771

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19739771

Country of ref document: EP

Kind code of ref document: A2